This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
COVID-19 remains endemic globally. Stay up to date with recommended boosters before travel. Entry requirements change frequently — check destination country requirements. Carry rapid test kits and know local healthcare options at your destination.
Respiratory illness caused by SARS-CoV-2 coronavirus. Ranges from asymptomatic to severe pneumonia. Vaccination requirements for travel vary by country and change frequently.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Cough | 68% | Mild | Early |
| Fever | 88% | Mild | Early |
| Loss of taste | 10% | Mild | Early |
| Loss of smell | 12% | Mild | Early |
| Arthralgia | 8% | Mild | Early |
| Chills | 11% | Mild | Early |
| Fatigue | 38% | Mild | Early |
| Headache | 14% | Mild | Early |
| Loss of appetite | 20% | Mild | Early |
| Myalgia | 15% | Mild | Early |
| Productive cough | 34% | Mild | Early |
| Sore throat | 14% | Mild | Early |
| Diarrhea | 4% | Mild | Early |
| Dizziness | 9% | Mild | Early |
| Nasal congestion | 5% | Mild | Early |
| Nausea | 5% | Mild | Early |
| Rhinorrhea | 4% | Mild | Early |
| Vomiting | 4% | Mild | Early |
| Shortness of breath | 19% | Severe | Peak |
| Chest tightness | 12% | Moderate | Peak |
| Confusion | 2% | Severe | Peak |
| Hemoptysis | 1% | Severe | Peak |
| Tachycardia | 7% | Moderate | Peak |
| Abdominal pain | 3% | Mild | Peak |
| Hypotension | 1.5% | Critical | Peak |
| Wheezing | 4% | Moderate | Peak |
| Conjunctivitis | 2% | Mild | Any phase |
COVID-19 (Coronavirus Disease 2019) is an acute respiratory and systemic infectious disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a betacoronavirus of the family Coronaviridae. First identified in Wuhan, China, in December 2019, it rapidly spread globally and was declared a pandemic by WHO on 11 March 2020.
SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA virus that enters human cells via the angiotensin-converting enzyme 2 (ACE2) receptor, facilitated by the transmembrane serine protease TMPRSS2. The spike (S) protein mediates cell entry and is the primary target of neutralizing antibodies and vaccines. The virus has undergone continuous evolution, generating Variants of Concern (VOCs) — Alpha, Beta, Delta, Omicron — each with distinct transmissibility, immune evasion, and pathogenicity profiles.
COVID-19 has caused the most significant global health emergency in a century, with over 770 million confirmed cases and 7 million recorded deaths (WHO, through 2024). The true mortality toll, including excess deaths, is estimated at 15–25 million. The disease has a remarkably broad clinical spectrum, ranging from asymptomatic infection to acute respiratory distress syndrome (ARDS), multi-organ failure, and death, with long-term sequelae (Long COVID) affecting an estimated 10–20% of those infected.
Causative agent: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), an enveloped betacoronavirus. Multiple lineages and sub-lineages circulate globally, with Omicron-derived variants predominant since 2022.
Transmission: Primarily via respiratory droplets and aerosols generated during breathing, speaking, coughing, and sneezing. Transmission efficiency is highest in indoor, poorly ventilated spaces. Fomite transmission is possible but considered a minor route. Pre-symptomatic and asymptomatic transmission contribute substantially to spread.
Incubation period: 2–14 days, with a median of approximately 5 days for earlier variants. Omicron and subsequent variants show a shorter median incubation of ~3 days.
Global burden: >770 million confirmed cases and >7 million recorded deaths worldwide (2020–2024). The pandemic prompted unprecedented global responses including lockdowns, travel restrictions, accelerated vaccine development, and restructured healthcare delivery.
Key facts:
Case-fatality rate: approximately 0.5–1% overall (highly age-dependent; >10% in unvaccinated elderly during early waves, <0.1% in vaccinated younger adults with Omicron)
30–40% of infections are asymptomatic
Effective treatments exist for both early disease (nirmatrelvir/ritonavir) and severe disease (dexamethasone, tocilizumab)
Vaccines dramatically reduce severe disease, hospitalization, and death
Long COVID affects an estimated 10–20% of infected individuals with symptoms persisting >3 months
SARS-CoV-2 continues to circulate globally as an endemic respiratory pathogen with seasonal waves
Seek immediate emergency medical care if a person with confirmed or suspected COVID-19 develops any of the following warning signs:
Respiratory emergency:
Difficulty breathing or shortness of breath at rest or with minimal activity
Oxygen saturation (SpO₂) below 94% on pulse oximetry at sea level (below 90% at altitude)
Persistent chest pain or pressure that is not relieved by position changes
Inability to speak in full sentences due to breathlessness
Bluish discoloration (cyanosis) of the lips, face, or nail beds
New-onset rapid breathing (respiratory rate >30 breaths/min in adults)
Neurological warning signs:
New confusion, disorientation, or inability to stay awake
Sudden difficulty speaking or understanding speech
New-onset seizures
Severe, persistent headache unresponsive to standard analgesics (consider cerebral venous sinus thrombosis)
Cardiovascular warning signs:
New irregular heartbeat, palpitations with lightheadedness
Chest pain suggestive of myocarditis or pulmonary embolism (sharp, pleuritic, worsening with inspiration)
Cold, pale, or mottled extremities
Signs of deep vein thrombosis: unilateral leg swelling, warmth, pain
Other critical warning signs:
Inability to tolerate oral fluids with signs of dehydration
Persistent fever >39.5°C unresponsive to antipyretics after 3 days
Rapid clinical deterioration after initial improvement (may suggest secondary bacterial infection or hyperinflammation)
High-risk individuals requiring lower threshold for emergency evaluation: Age >65, immunocompromised, unvaccinated, obesity (BMI >30), chronic lung/heart/kidney disease, diabetes, pregnancy.
Most common signs and symptoms
COVID-19 presents with a remarkably broad clinical spectrum. Approximately 30–40% of infections are entirely asymptomatic, though these individuals may still transmit the virus. Symptom profiles have evolved with successive variants.
Common symptoms (present in >50% of symptomatic cases):
Fever or chills (often low-grade with Omicron variants)
Dry cough
Fatigue and malaise
Myalgia (muscle pain) and arthralgia
Headache
Sore throat (increasingly prominent with Omicron)
Moderately common symptoms (10–50%):
Anosmia (loss of smell) and ageusia (loss of taste) — highly characteristic of earlier variants (Alpha, Delta); less common with Omicron
Nasal congestion and rhinorrhea
Gastrointestinal symptoms: nausea, vomiting, diarrhea (more common in children)
Dyspnea (shortness of breath) — onset typically on days 5–8 of illness and may signal progression
Severe disease presentation (5–15% of symptomatic unvaccinated adults):
Progressive dyspnea with hypoxemia (often "silent hypoxia" — SpO₂ <94% without proportionate respiratory distress)
Bilateral ground-glass opacities and consolidation on chest imaging
Acute respiratory distress syndrome (ARDS) requiring supplemental oxygen or mechanical ventilation
Hyperinflammatory syndrome with cytokine storm features: persistent fever, marked ferritin/CRP/IL-6 elevation, lymphopenia
Variant-specific patterns:
Delta: More severe lower respiratory tract disease, higher viral loads, shorter incubation
Omicron and descendants: Predominantly upper respiratory symptoms (sore throat, rhinorrhea), less anosmia, generally milder but still capable of causing severe disease in vulnerable populations
Pediatric presentation: Generally milder. Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare post-infectious hyperinflammatory condition (2–6 weeks after infection) with fever, gastrointestinal symptoms, cardiac involvement, and shock.
Knowing the symptoms is the first step to a quick response.
Typical disease course:
Biphasic pattern: Initial viral replication phase (days 1–5) → inflammatory/immune phase (days 5–12). Clinical deterioration often occurs during the inflammatory transition.
How this disease is identified
Diagnosis of COVID-19 relies on the combination of clinical presentation, epidemiological context, and virological or serological testing.
Molecular testing (gold standard):
RT-PCR (reverse transcription polymerase chain reaction): Performed on nasopharyngeal swab (preferred), oropharyngeal swab, or saliva. Sensitivity ~95–98% with proper sampling. Detects viral RNA; may remain positive for weeks after infectious period (shedding of non-viable RNA fragments). Turnaround: 4–24 hours in most laboratories.
Other NAATs (nucleic acid amplification tests): Isothermal amplification methods (LAMP, TMA) offer faster results with comparable sensitivity.
Rapid antigen detection tests (Ag-RDT):
Lateral flow immunoassay detecting SARS-CoV-2 nucleoprotein antigen
Results in 15–30 minutes; suitable for point-of-care and self-testing
Sensitivity: 70–90% (highest during peak viral load, days 1–5 of symptoms); specificity >99%
A negative rapid test in a symptomatic patient does not rule out COVID-19 — confirmatory PCR should be considered if clinical suspicion is high
Positive rapid antigen tests are highly reliable and generally do not require PCR confirmation
Serological testing (antibody detection):
IgM/IgG against spike protein or nucleoprotein; detectable from ~7–14 days after symptom onset
Not useful for acute diagnosis; used for seroprevalence surveys and epidemiological studies
Anti-nucleoprotein antibodies indicate prior infection (not induced by most vaccines); anti-spike antibodies may reflect infection or vaccination
Chest imaging:
Not recommended for diagnosis but valuable for assessing disease severity in hospitalized patients
Characteristic CT findings: bilateral, peripheral, ground-glass opacities predominantly in lower lobes; "crazy paving" pattern; consolidation in advanced disease
Chest X-ray: bilateral interstitial infiltrates; less sensitive than CT
Laboratory markers for severity stratification (hospitalized patients):
Available treatment methods
Treatment of COVID-19 is stratified by disease severity and patient risk factors. Therapeutic options have expanded substantially since 2020, and evidence-based guidelines are regularly updated.
Mild-to-moderate disease in high-risk patients (outpatient):
Nirmatrelvir/ritonavir (Paxlovid): Oral protease inhibitor combination; initiated within 5 days of symptom onset. Reduces hospitalization/death by ~89% in high-risk unvaccinated patients. Drug interactions (CYP3A4 inhibition) require careful medication review. "Paxlovid rebound" (symptom recurrence) occurs in ~10–15% but is usually mild.
Remdesivir: 3-day IV course for high-risk outpatients; reduces hospitalization by ~87% when given early.
Molnupiravir: Oral option when nirmatrelvir/ritonavir and remdesivir are unavailable; lower efficacy (~30% reduction in hospitalization).
Moderate-to-severe disease (hospitalized, requiring supplemental oxygen):
Dexamethasone 6 mg daily for up to 10 days: Cornerstone of therapy for patients requiring oxygen. Reduced 28-day mortality by one-third in the RECOVERY trial. Contraindicated in patients NOT requiring oxygen (may worsen outcomes).
Remdesivir: 5-day course for hospitalized patients; modest reduction in time to recovery.
Anticoagulation: Prophylactic-dose heparin for all hospitalized patients. Therapeutic-dose heparin for non-critically-ill hospitalized patients reduces organ-support-free days (ACTIV-4a/REMAP-CAP).
Critical disease (ICU, mechanical ventilation):
Dexamethasone (or equivalent corticosteroid) remains standard
Tocilizumab or baricitinib: IL-6 receptor blocker or JAK inhibitor added to corticosteroids for patients with rapidly increasing oxygen requirements or systemic inflammation (CRP ≥75 mg/L). Reduces mortality and need for mechanical ventilation.
Prone positioning: Improves oxygenation in ARDS; recommended for ≥12–16 hours/day
Lung-protective ventilation: Low tidal volumes (6 mL/kg predicted body weight), plateau pressure <30 cmH₂O
Therapies no longer recommended: Hydroxychloroquine, ivermectin, lopinavir/ritonavir, convalescent plasma (for most indications) — all have been shown to lack clinical benefit in rigorous trials.
Supportive care for all patients: Adequate hydration, antipyretics (paracetamol preferred), monitoring of oxygen saturation, and early mobilization when possible.
Most cases are effectively treated with early diagnosis.
How to protect yourself
Prevention of COVID-19 employs a layered approach combining vaccination, respiratory precautions, and environmental measures. As SARS-CoV-2 transitions to endemic circulation, prevention strategies focus on reducing severe outcomes rather than preventing all infections.
Vaccination (most important intervention):
mRNA vaccines (Pfizer-BioNTech BNT162b2, Moderna mRNA-1273) and protein subunit vaccines (Novavax NVX-CoV2373) are the primary platforms in current use, updated annually to match circulating variants
Primary series + updated boosters provide strong protection against severe disease, hospitalization, and death (~90% reduction), with more modest and waning protection against symptomatic infection (~50–70%, declining over months)
WHO and major health authorities recommend updated (monovalent, variant-adapted) boosters annually, particularly for high-risk groups: age ≥65, immunocompromised, pregnant women, healthcare workers, and those with chronic conditions
Vaccine safety profile remains favorable; myocarditis/pericarditis risk (primarily young males after mRNA dose 2) is rare (~1–5 per 100,000) and generally self-limited
Respiratory and personal protective measures:
Masks: Well-fitting N95/FFP2 or high-quality surgical masks provide significant source and personal protection, particularly in crowded indoor settings during high-transmission periods
Hand hygiene: Regular handwashing with soap (≥20 seconds) or alcohol-based hand sanitizer (≥60% ethanol)
Respiratory etiquette: Covering cough/sneeze, avoiding touching face
Environmental measures:
Ventilation: Adequate indoor air exchange (≥6 ACH) or use of portable HEPA air purifiers significantly reduces aerosol transmission
Distancing: Maintaining physical distance reduces droplet exposure, though aerosol transmission can occur at greater distances in poorly ventilated spaces
Post-exposure and outbreak management:
Testing after known exposure (day 3–5 post-exposure or at symptom onset)
Isolation for confirmed cases: minimum 5 days from symptom onset (or positive test if asymptomatic), with return to activities guided by symptom resolution and local guidelines
Antiviral prophylaxis is not currently recommended for routine post-exposure use
Preparation is the best protection.
As of 2024–2025, most COVID-19-related international travel restrictions have been lifted. However, SARS-CoV-2 continues to circulate globally with periodic waves, and travelers should take evidence-based precautions.
Pre-travel preparation:
Ensure vaccination is up to date, including the most recent variant-adapted booster, particularly if traveling to regions with high transmission or limited healthcare infrastructure
Travelers with chronic conditions, immunocompromised status, or advanced age should consult their healthcare provider about carrying a supply of nirmatrelvir/ritonavir (Paxlovid) for early treatment if infected during travel
Pack rapid antigen tests, high-quality masks (N95/FFP2), and hand sanitizer (≥60% alcohol)
Verify destination country entry requirements — while most countries no longer require vaccination proof or testing, some may reinstate measures during surges
During travel:
Wear a well-fitting mask in crowded, poorly ventilated settings (airports, public transit, indoor gatherings), particularly during periods of known high transmission
Frequent hand hygiene, especially before eating and after touching shared surfaces
Maintain awareness of local COVID-19 situation through WHO, CDC, or ECDC situation reports
Ensure adequate travel health insurance that covers COVID-19 hospitalization and medical evacuation
Air travel considerations:
Modern aircraft HEPA filtration systems reduce but do not eliminate airborne transmission risk
Boarding, deplaning, and ground delays (when ventilation is reduced) represent higher-risk periods
Consider wearing a mask throughout the flight, particularly on long-haul routes
If you develop symptoms while traveling:
Self-test with a rapid antigen test
If positive and at high risk for severe disease, seek medical care promptly for antiviral treatment (most effective within 5 days of symptom onset)
Isolate per local guidelines and postpone onward travel if possible
Notify close contacts and travel companions
Statistics and geographic data
COVID-19 represents the most significant pandemic since the 1918 influenza. After its emergence in late 2019, SARS-CoV-2 spread to every country within months and has transitioned to endemic circulation with seasonal patterns.
Pandemic timeline and burden:
2020: Emergence and global spread; ~83 million confirmed cases, ~1.8 million deaths by year-end. Pre-vaccine era with reliance on non-pharmaceutical interventions (lockdowns, masking, distancing).
2021: Vaccine rollout began; Alpha and Delta variants drove severe waves. ~280 million cumulative cases by year-end. Delta (B.1.617.2) caused devastating surges in India, Southeast Asia, and parts of Europe.
2022: Omicron (B.1.1.529) and sub-lineages became dominant globally. Dramatically higher transmissibility but lower severity per case (partly due to population immunity). Record case counts but declining mortality.
2023–2024: WHO declared an end to the public health emergency of international concern (PHEIC) on 5 May 2023. Ongoing endemic transmission with periodic waves driven by new sub-lineages (XBB, EG.5, JN.1, KP.2). Seasonal patterns emerging in temperate regions (winter peaks).
Cumulative global impact (through 2024):
770 million confirmed cases (true infections estimated at 3–5× higher due to underascertainment)
7 million recorded deaths; excess mortality estimates suggest 15–25 million pandemic-attributable deaths
Highest recorded case counts: United States, India, France, Germany, Brazil, Japan, South Korea
Variant evolution:
SARS-CoV-2 continues to evolve, predominantly within the Omicron lineage. Immune evasion (through spike mutations) drives new waves, while population-level immunity limits severe disease burden.
The JN.1 lineage and descendants (KP.2, KP.3, LB.1) dominated circulation in 2024, with continued antigenic drift.
Current status:
Who is most at risk
Risk factors for COVID-19 infection, severe disease, and mortality have been extensively characterized through large-scale epidemiological studies and meta-analyses.
Risk factors for severe disease and death:
Age: The single strongest predictor of severe outcomes. Risk of hospitalization and death increases exponentially after age 50, with those ≥80 years having 20–100× higher mortality than those aged 18–29. Age-specific IFR ranges from ~0.002% (age 10) to >10% (age ≥80) in unvaccinated populations.
Vaccination status: Unvaccinated individuals have 5–20× higher risk of hospitalization and 10–40× higher mortality compared to those with up-to-date vaccination (varies by variant and time since last dose).
Immunocompromised status: Solid organ transplant recipients, hematologic malignancy, HIV (CD4 <200), active chemotherapy, high-dose corticosteroids, and biologic immunosuppressants all significantly increase risk. Reduced vaccine effectiveness compounds the risk.
Chronic conditions: Chronic kidney disease (especially dialysis), chronic obstructive pulmonary disease, heart failure, coronary artery disease, type 2 diabetes (especially HbA1c >8%), obesity (BMI ≥30; risk increases progressively), sickle cell disease, neurological conditions (dementia, stroke), and liver cirrhosis.
Pregnancy: Increased risk of ICU admission, mechanical ventilation, and preterm delivery, particularly in unvaccinated women with comorbidities.
Risk factors for Long COVID:
Female sex (1.5–2× higher risk than males)
Severity of acute infection (hospitalized patients have higher risk, but Long COVID also occurs after mild disease)
Pre-existing depression or anxiety
Type 2 diabetes and high BMI
Epstein-Barr virus reactivation during acute COVID-19
Autoantibody formation
Lower SARS-CoV-2 vaccination doses prior to infection (vaccination reduces Long COVID risk by ~50%)
Socioeconomic and structural risk factors:
Crowded living conditions, inability to work remotely, limited access to healthcare and testing
Racial and ethnic minorities in many countries experienced disproportionate infection and death rates, driven by structural inequities rather than biological differences
Potential complications
COVID-19 can cause complications affecting virtually every organ system, both during the acute illness and in the post-acute phase (Long COVID). The risk of complications is substantially reduced by vaccination.
Pulmonary complications:
ARDS (acute respiratory distress syndrome): Develops in ~15–30% of hospitalized patients (pre-Omicron data); characterized by diffuse alveolar damage, refractory hypoxemia, and the need for mechanical ventilation. Mortality of COVID-19 ARDS: 30–50% in mechanically ventilated patients.
Pulmonary embolism: Incidence 5–15% in hospitalized patients, even higher in ICU. COVID-19 induces a prothrombotic state (endotheliopathy, complement activation, NETosis). Routine thromboprophylaxis is standard of care.
Pulmonary fibrosis: Persistent radiographic and functional abnormalities in 20–30% of patients at 3–6 months post-hospitalization, though most improve over time.
Cardiovascular complications:
Myocarditis: Elevated troponin in 20–40% of hospitalized patients; clinically significant myocarditis in 1–5%. Can manifest as arrhythmias, heart failure, or cardiogenic shock.
Thromboembolic events: Deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. D-dimer elevation is a key prognostic marker.
Arrhythmias: Atrial fibrillation (new-onset in ~10% of hospitalized elderly), QT prolongation.
Neurological complications:
Anosmia/ageusia (partial or complete; usually recovers within weeks to months)
Stroke (ischemic or hemorrhagic, 1–3% of hospitalized patients)
Guillain-Barré syndrome (rare)
"Brain fog," cognitive dysfunction, and fatigue (prominent Long COVID features)
Encephalitis and seizures (rare, more common in severe disease)
Renal complications:
Long COVID (Post-Acute Sequelae of SARS-CoV-2, PASC):
Affects an estimated 10–20% of infected individuals with symptoms persisting >3 months
Most common symptoms: fatigue, exertional intolerance, cognitive dysfunction ("brain fog"), dyspnea, sleep disturbance, joint/muscle pain, anxiety/depression
Pathophysiology is multifactorial: viral persistence, autoimmunity, microbiome disruption, mitochondrial dysfunction, microvascular injury
No validated specific treatment; management is symptomatic and rehabilitative
Vaccination prior to infection reduces Long COVID risk by approximately 50%
Expected outcomes and recovery
Overall infection-fatality rate (IFR): 0.1–0.5% (varies by age, vaccination status, variant).
Age-stratified IFR (unvaccinated, pre-Omicron): <40 years: <0.1%; 40–60: 0.5–1%; 60–70: 2–5%; >80: 10–15%.
With vaccination: Severe disease and death reduced by 70–90%+.
Risk factors for severe disease: Age ≥65, obesity, diabetes, cardiovascular disease, chronic lung disease, immunosuppression, pregnancy.
Long COVID (post-acute sequelae): 10–30% of symptomatic cases report persistent symptoms at 3 months (fatigue, cognitive dysfunction, dyspnea, dysautonomia). Decreasing incidence with Omicron and vaccination.
Current era (2024–2025): Widespread population immunity (hybrid: infection + vaccination). Disease is predominantly mild. Severe disease concentrated in elderly, immunocompromised, and unvaccinated populations.
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.